Spark Therapeutics Enters into Definitive Merger Agreement with Roche
25 févr. 2019 01h00 HE
|
Spark Therapeutics, Inc.
Roche to acquire Spark Therapeutics for $114.50 per share representing a total equity value of $4.8 billion Spark Therapeutics will continue its operations in Philadelphia as an independent company...
Spark Therapeutics Reports 2018 Financial Results and Recent Business Progress
19 févr. 2019 07h30 HE
|
Spark Therapeutics, Inc.
PHILADELPHIA, Feb. 19, 2019 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ: ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease,...
Spark Therapeutics to Host Conference Call on Tuesday, Feb. 19 at 8:30 a.m. ET to Discuss 2018 Results and Recent Business Highlights
12 févr. 2019 07h30 HE
|
Spark Therapeutics, Inc.
PHILADELPHIA, Feb. 12, 2019 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ: ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease,...
Spark Therapeutics Announces Presentation of Preclinical Data in Pompe Disease and CLN2 Disease at 15th Annual WORLDSymposium™
31 janv. 2019 07h30 HE
|
Spark Therapeutics, Inc.
PHILADELPHIA, Jan. 31, 2019 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease,...
Spark Therapeutics to Participate in J.P. Morgan Healthcare Conference
02 janv. 2019 07h30 HE
|
Spark Therapeutics, Inc.
PHILADELPHIA, Jan. 02, 2019 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ: ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease,...
Spark Therapeutics Announces Updated Data on SPK-8011 from Ongoing Phase 1/2 Dose-escalation Clinical Trial in Hemophilia A at 60th American Society of Hematology (ASH) Annual Meeting and Exposition
02 déc. 2018 19h30 HE
|
Spark Therapeutics, Inc.
Preliminary Phase 1/2 data for investigational SPK-8011 for hemophilia A show dramatic reductions in bleeds and infusions for first 12 participants with an encouraging safety profile, as of Nov. 2,...
European Commission Approves Spark Therapeutics’ LUXTURNA® (voretigene neparvovec), a One-time Gene Therapy for Inherited Retinal Disease Caused by Confirmed Biallelic RPE65 Mutations
23 nov. 2018 01h15 HE
|
Spark Therapeutics, Inc.
LUXTURNA is first gene therapy for a genetic disease approved in both the U.S. and EU LUXTURNA is first and only gene therapy approved in EU for patients with an inherited retinal disease (IRD) ...
Spark Therapeutics Reports Third Quarter 2018 Financial Results and Recent Business Progress
06 nov. 2018 07h30 HE
|
Spark Therapeutics, Inc.
PHILADELPHIA, Nov. 06, 2018 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ: ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease,...
Spark Therapeutics to Host Conference Call on Tuesday, Nov. 6 at 8:30 a.m. ET to Discuss Third Quarter Results and Recent Business Highlights
30 oct. 2018 07h30 HE
|
Spark Therapeutics, Inc.
PHILADELPHIA, Oct. 30, 2018 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ: ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease,...
Spark Therapeutics Presents Three Post-hoc Analyses from Phase 3 Clinical Trial of LUXTURNA® (voretigene neparvovec-rzyl) at American Academy of Ophthalmology Annual Meeting
29 oct. 2018 16h53 HE
|
Spark Therapeutics, Inc.
Use of different measurement for best-corrected visual acuity of participants in the Phase 3 clinical trial of LUXTURNA achieved statistically significant improvement versus control group Mutation...